Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
Corresponding author: Mohammed S.B. Huda, bobby.huda@bartshealth.nhs.uk.
Mohammed S B
MS
Huda
Stephanie A
SA
Amiel
Paul
P
Ross
Simon J B
SJ
Aylwin
D000970:Antineoplastic Agents / Q000627:therapeutic use; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007211:Indoles / Q000627:therapeutic use*; D061267:Insulin Aspart / Q000627:therapeutic use; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000627:therapeutic use; D008875:Middle Aged; D018358:Neuroendocrine Tumors / Q000150:complications / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000150:complications / Q000188:drug therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib
D000970:Antineoplastic Agents; D007004:Hypoglycemic Agents; D007211:Indoles; D049528:Insulin, Long-Acting; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000069036:Insulin Glargine; D061267:Insulin Aspart; D000077210:Sunitinib